Semaglutide suppresses neuroinflammation, reduces oxidative injury, and modifies AD biomarkers (p-tau, t-tau, neurogranin) in human CSF, though Phase 3 AD trials did not meet primary cognitive endpoints.
Biomarkers improved, cognition didn'tSemaglutide reduced AD CSF biomarkers in humans but Phase 3 trials missed the CDR-SB cognitive primary endpoint
What the researchers found
Semaglutide reduced CSF p-tau, t-tau, neurogranin, and inflammation marker YKL-40 in humans, but Phase 3 AD trials did not meet the CDR-SB cognitive primary endpoint despite favorable biomarker modulation.
Why it matters
If semaglutide can modify neuroinflammation across multiple diseases, it could become the first broadly applicable neuroprotective drug—but the disconnect between biomarker improvement and clinical endpoints needs resolution.
How the study worked
Comprehensive narrative review of preclinical and emerging clinical evidence for semaglutide's neuroprotective effects across neurodegenerative diseases.
What this study cannot tell us
Phase 3 AD trials failed primary endpoint. BBB penetration is limited. Most non-AD evidence is preclinical. Extrapolation across different diseases requires disease-specific validation.
How to read the evidence
Comprehensive review integrating preclinical, biomarker, and Phase 3 trial evidence. Nuanced picture of promise tempered by clinical endpoint failure.
When this study was published
Published in 2025, incorporating the latest Phase 3 AD trial results.
The bigger picture
The biomarker success but clinical endpoint failure in AD mirrors challenges across neurodegeneration—modifying disease biology may not immediately translate to cognitive improvement, requiring longer trials or different endpoints.
Questions still open
- Would longer semaglutide treatment in AD eventually show cognitive benefits?
- Should clinical trials for semaglutide in MS, ALS, and PD be prioritized?
- Is the disconnect between biomarkers and cognition due to insufficient brain penetration or wrong endpoints?
Common questions
Can semaglutide treat Alzheimer's or Parkinson's?
Why did the Alzheimer's trials fail if the biomarkers improved?
Read the original research
Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 75(1), 13
Citation
Evola, Vito; Parmar, Mayur S. (2026). Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 75(1), 13. https://doi.org/10.1007/s00011-025-02166-6